BLAINTRAVENOUSSOLUTION
Approved
Jun 2019
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
4/8 — Partial
MYXREDLIN (insulin human) by Baxter is insulin, including myxredlin is the regulation of glucose metabolism. Approved for diabetes mellitus, type 1 diabetes mellitus, type 2 diabetes mellitus. First approved in 2019.
Drug data last refreshed 19h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MYXREDLIN is an intravenous insulin human solution approved in 2019 for the treatment of Type 1 and Type 2 Diabetes Mellitus. It works by regulating glucose metabolism through stimulation of peripheral glucose uptake and inhibition of hepatic glucose production. The drug also inhibits lipolysis and proteolysis while enhancing protein synthesis.
Peak
Product is at peak lifecycle stage with moderate competitive pressure (30/100), indicating stable but challenged commercial operations requiring defensive strategies.
Mechanism of Action
insulin, including MYXREDLIN is the regulation of glucose metabolism. Insulins lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis and proteolysis, and enhances protein…
Pharmacologic Class:
Insulin
Indications (3)
Worked on MYXREDLIN at Baxter? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.